- The European Commission has granted marketing authorization to Dr. Reddy’s Laboratories for its biosimilar AVT03.
- The approval covers treatments for osteoporosis and prevention of bone complications in cancer patients.
- This move strengthens the company’s European portfolio following a strategic licensing deal with Alvotech.
Regulatory Milestone in Europe
Dr. Reddy’s Laboratories has successfully cleared a major regulatory hurdle in the European Union. The European Commission (EC) has officially authorized the marketing of AVT03, a biosimilar to the drug Denosumab. This final decision validates the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) in September 2025, confirming the product meets the stringent safety and efficacy standards required for the region.
Also Read: Steel Imports Crash 34%, Exports Boom: JSW Steel Breakout?
Dual Treatment Indications
The newly approved biosimilar addresses two critical medical needs under different brand applications. The first indication is equivalent to Prolia, which is widely used to treat osteoporosis in postmenopausal women and men at high risk of fractures. The second indication mirrors Xgeva, a treatment designed to prevent serious bone-related complications in adult patients battling advanced cancers. This dual approval allows Dr. Reddy’s to serve a broad spectrum of patients within the bone health sector.
Strategic Partnership with Alvotech
This commercial success is built on a robust partnership between Dr. Reddy’s and the developer, Alvotech. Under the terms of their agreement, Alvotech is responsible for the development and manufacturing of the drug, ensuring high-quality production. In return, Dr. Reddy’s holds the semi-exclusive rights to commercialize the product across Europe and the United Kingdom, leveraging its established distribution network to bring the drug to market.
Also Read: RIL Hits Record High: JP Morgan Sees ₹1,727 Target
Positive Market Sentiment
Analysts tracking the pharmaceutical sector view this development as a definitive positive for Dr. Reddy’s. The approval is expected to significantly strengthen the company’s European business vertical by unlocking a fresh revenue stream in a high-value market. By introducing these biosimilars, Dr. Reddy’s is positioned to capture market share from established players, improving its growth outlook and sentiment among investors.
Aditya Gaur is the founder of FinanceXaditya and a seasoned stock market investor with over 7 years of experience. Known for building India’s first public dividend growth portfolio showcase, he shares time-tested strategies and real insights that help everyday investors create wealth. With 50,000+ followers across social media, Aditya has become a trusted voice in personal finance and long-term investing.
